uniQure/QURE

$4.69

0.86%
-
1D1W1MYTD1YMAX

About uniQure

Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.

Ticker

QURE

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Matthew Kapusta

Employees

480

Headquarters

Amsterdam, Netherlands

uniQure Metrics

BasicAdvanced
$229M
Market cap
-
P/E ratio
-$6.20
EPS
1.07
Beta
-
Dividend rate
$229M
1.067
$21.00
$4.25
831K
9.39
9.269
345.829
345.829
-8.72%
-42.38%
-106.11%
-46.71%
12.059
1.56
3.705
-82.73%
-85.43%
-24.97%

What the Analysts think about uniQure

Analyst Ratings

Majority rating from 13 analysts.
Buy

Price Targets

Average projection from 12 analysts.
306.82% upside
High $28.00
Low $6.00
$4.69
Current price
$19.08
Average price target

uniQure Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-780.95% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$8.4M
27.27%
Net income
-$66M
-10.38%
Profit margin
-780.95%
-29.59%

uniQure Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 6.25%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$1.44
-$1.88
-$1.53
-$1.36
-
Expected
$2.05
-$0.85
-$1.46
-$1.28
-$1.25
Surprise
-170.23%
121.38%
5.2%
6.25%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for uniQure stock?

uniQure (QURE) has a market cap of $229M as of May 30, 2024.

What is the P/E ratio for uniQure stock?

The price to earnings (P/E) ratio for uniQure (QURE) stock is 0 as of May 30, 2024.

Does uniQure stock pay dividends?

No, uniQure (QURE) stock does not pay dividends to its shareholders as of May 30, 2024.

When is the next uniQure dividend payment date?

uniQure (QURE) stock does not pay dividends to its shareholders.

What is the beta indicator for uniQure?

uniQure (QURE) has a beta rating of 1.07. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the uniQure stock price target?

The target price for uniQure (QURE) stock is $19.08, which is 306.82% above the current price of $4.69. This is an average based on projections from 12 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell uniQure stock

Buy or sell uniQure stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing